MedTrace Logo

Effect of Lu AF35700 in Patients With Treatment-resistant Schizophrenia

NCT02717195 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1098

Last updated 2019-11-25

Study results available
· View outcomes & findings →

Summary

To evaluate the efficacy of 10 and 20 mg/day of Lu AF35700 on schizophrenia symptoms in patients with treatment-resistant schizophrenia (TRS)

Conditions

Interventions

DRUG

Risperidone

4-6 mg/day, encapsulated tablets, orally

DRUG

Olanzapine

15-20 mg/day, encapsulated tablets, orally

DRUG

Lu AF35700

10 mg/day, encapsulated tablets, orally

DRUG

Lu AF35700

20 mg/day, encapsulated tablets, orally

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Principal Investigators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-30
Primary Completion
2018-08-30
Completion
2018-10-08

Countries

  • United States
  • Bulgaria
  • Canada
  • Czechia
  • Estonia
  • Finland
  • Mexico
  • Poland
  • Romania
  • Russia
  • Serbia
  • Slovakia
  • Spain
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02717195 on ClinicalTrials.gov